Interstitial lung diseases (ILDs) represent a heterogeneous group of more than 200 lung disorders, primarily affecting the pulmonary interstitium. These disorders are characterized by fibrosis, inflammation, or a combination of both. ILDs are often complex, requiring a comprehensive understanding of their causes, symptoms, and treatment options.
ILDs can be idiopathic or associated with a myriad of causes, such as connective tissue diseases, occupational and environmental exposures, drugs, and radiation. Idiopathic pulmonary fibrosis (IPF) is the most common idiopathic ILD, with a poorly understood etiology. It is believed that genetic predisposition, aging, and environmental factors like smoking contribute to the development of IPF.
ILDs typically present with insidious onset of dyspnea and non-productive cough. Physical examination may reveal inspiratory crackles and finger clubbing. High-resolution computed tomography (HRCT) is the gold standard for diagnosis, showing characteristic patterns such as reticular opacities, honeycombing, and ground-glass opacities. Pulmonary function tests often reveal a restrictive pattern with reduced diffusion capacity.
Management of ILDs depends on the underlying cause. In cases of IPF, antifibrotic agents like pirfenidone and nintedanib have shown to slow disease progression. For ILDs associated with connective tissue diseases, immunosuppressive therapy is often beneficial. Lung transplantation remains the ultimate treatment for selected patients with advanced disease.
ILDs are a diverse group of lung disorders with varying etiologies and clinical presentations. A thorough understanding of the causes, symptoms, and treatment options is essential for optimal patient management. Future research should focus on elucidating the pathogenesis of idiopathic ILDs and developing novel therapeutic strategies.
1.
Injecting PD-1 Drug Directly Into Oral Precancers Shrinks Lesions
2.
Sevabertinib Approved for First-Line Mutated NSCLC
3.
After three years, responses to mounetuzumab in follicular lymphoma are still stable.
4.
FDA Bans Red Dye No. 3 From Foods, Ingested Drugs
5.
AI can identify women at risk of breast cancer years in advance: Study
1.
Revolutionizing Cancer Treatment: Advances in Immunotherapy and Cell Therapy
2.
Pediatric Tumor Microenvironment Evolution: Mechanisms, Clinical Impact, and Therapeutic Implications
3.
Hematopoietic Stem Cell Activity Biomarkers in Aging
4.
Bone-Marrow Immune Cell Competition: Mechanisms, Clinical Implications, and Emerging Therapeutic Perspectives
5.
The Truth About TAR Syndrome: Understanding the Rare Genetic Disorder
1.
International Conference on Innovations in Critical Care for Oncology and Cardiology
2.
International Conference on Oncology, Cardiology and Critical Care Policy
3.
International Conference on Oncology, Cancer Prevention and Public Health
4.
International Conference on Cancer Nursing and Rehabilitation Strategies
5.
International Conference on Best Practices in Oncology, Cardiology and Critical Care
1.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part VIII
2.
A New Era in Managing Cancer-Associated Thrombosis
3.
Emerging Concepts in Hematology
4.
The Reign of the CROWN Trial and the Dawn of a New Era in Frontline Management- Further Discussion
5.
An Eagles View - Evidence-based Discussion on Iron Deficiency Anemia- Panel Discussion III
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation